proteomic biomarkers
Using a protein biomarker signature, the company is advancing a CHK1/2 inhibitor that Eli Lilly out-licensed after seeing limited responses in genomic subgroups.
Proteomic Signature Shows Promise in Identifying Ovarian Cancer Patients Who Won't Respond to Chemo
Premium
Where single biomarkers have failed to identify refractory ovarian cancers before treatment, a 64-protein signature could with 98 percent specificity.